Serevent is a medical product produced by GlaxoSmithKline. One dose of Serevent contains: Salmeterol (xinafoate, micronized) - 25 mcg. Other components: trichlorofluoromethane, lecithin, dichlorodifluoromethane.
Pharmachologic Effect of Serevent
Regular intake of the drug provides a persistent improvement in lung function, reducing the severity of the airway obstruction syndrome and nighttime attacks of bronchial asthma. Serevent in therapeutic doses does not have an effect on the cardiovascular system. It is proved that Salmeterol causes a prolonged (up to 12 hours) bronchial dilatation in patients with reversible airway obstruction.
Serevent suppresses early and late reactivity of the bronchi. After a single application weakens the hyperactive response of the bronchi, which indicates an anti-inflammatory and bronchodilating activity.
The onset of action is observed after 5-10 minutes from the moment of inhalation. Broncholytic effect lasts 12 hours.
Serevent is intended for use solely in the form of inhalations. The drug is intended for regular use.
Serevent in adults is prescribed in a dose of 50 mcg 2 times / day. If necessary, the dose of the drug can be increased to 100 mcg 2 times / day.
Children over the age of 4 years are prescribed 50 mcg 2 times / day
From The Respiratory System
The development of paradoxical bronchospasm is possible (in this case, immediately cancel the drug and prescribe an alternative therapy)
From The Cardiovascular System
Possible resctions: headache, tachycardia, (it should be borne in mind that these symptoms may not be associated with taking the drug); in predisposed patients - cardiac arrhythmias (ciliary arrhythmia, supraventricular tachycardia and extrasystole).
Pregnancy And Breastfeeding
The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother exceeds the potential risk to the fetus or baby.
The drug is not used for cupping bronchospasm, it is prescribed only as a prolonged prophylaxis of asthma attacks, incl. night, and also with asthma physical effort.
Patients with thyrotoxicosis are appointed with cautiousness.
Patients with impaired renal function and elderly patients do not need to change the dose.
With the regular use of Seret, most patients usually have a reduced need for additional use of rescue inhalers.
Serevent in the form of an inhaler should be stored at a temperature of no higher than 30°C; avoid exposure to direct sunlight; Do not freeze. The expiration date of the metered aerosol containing 60 doses in the vial is 2 years; containing 120 doses in a vial - 3 years. The powdered inhaler in discalysers should be stored at a temperature not exceeding 25°C. Shelf life is 2 years.